论文部分内容阅读
目的探讨血浆RASSF1A基因(Ras association domain family 1 gene)和p16基因的启动子区异常甲基化与原发性肝癌关系。方法采用甲基化特异性PCR(MSP)法,对100例原发性肝癌(HCC)患者、30例乙肝患者、30例肝硬化患者和30名健康体检者血浆中RASSF1A和p16基因的启动子区异常甲基化状况进行检测。结果 HCC患者血浆RASSF1A和p16基因异常甲基化检出率分别为38.0%(38/100)和65.0%(65/100),而乙肝患者、肝硬化患者和健康体检者均未检出,与HCC组比较,差异均有统计学意义(P=0.000);Logistic回归分析发现,患者年龄、性别、血浆甲胎蛋白(AFP)、HBsAg、p16基因(RASSF1A基因)甲基化状况等与血浆中RASSF1A基因(p16基因)异常甲基化检测结果无关(P>0.05)。结论原发性肝癌患者血浆DNA中可检测到RASSF1A基因和p16基因的甲基化;RASSF1A基因和p16基因的甲基化检测对肝癌筛查有重要意义。
Objective To investigate the relationship between abnormal methylation of promoter regions of plasma RASSF1A gene and p16 gene in primary hepatocellular carcinoma. Methods The promoter of RASSF1A and p16 genes in plasma of 100 patients with primary liver cancer (HCC), 30 patients with hepatitis B, 30 patients with cirrhosis and 30 healthy controls were analyzed by methylation-specific PCR (MSP) District abnormal methylation status testing. Results The rates of abnormal methylation of RASSF1A and p16 genes in HCC patients were 38.0% (38/100) and 65.0% (65/100), respectively. However, none of hepatitis B patients, cirrhosis patients and healthy subjects were detected, HCC group, the differences were statistically significant (P = 0.000); Logistic regression analysis found that patients with age, gender, plasma AFP, HBsAg, p16 gene (RASSF1A gene methylation status and plasma RASSF1A gene (p16 gene) abnormal methylation test results (P> 0.05). Conclusion The methylation of RASSF1A gene and p16 gene can be detected in the plasma DNA of patients with primary liver cancer. The methylation of RASSF1A gene and p16 gene is of great significance for the screening of liver cancer.